Iversen P - Search Results

1

Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function.

Iversen P, Melezinek I, Schmidt A. Iversen P, et al. BJU Int. 2001 Jan;87(1):47-56. doi: 10.1046/j.1464-410x.2001.00988.x. BJU Int. 2001. PMID: 11121992 Review. No abstract available.

2

Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.

Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I. Iversen P, et al. J Urol. 2000 Nov;164(5):1579-82. J Urol. 2000. PMID: 11025708

3

The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study.

Tyrrell CJ, Blake GM, Iversen P, Kaisary AV, Melezinek I. Tyrrell CJ, et al. Among authors: iversen p. World J Urol. 2003 May;21(1):37-42. doi: 10.1007/s00345-003-0322-7. Epub 2003 Mar 22. World J Urol. 2003. PMID: 12756493

4

Quality of life issues relating to endocrine treatment options.

Iversen P. Iversen P. Eur Urol. 1999;36 Suppl 2:20-6. doi: 10.1159/000052339. Eur Urol. 1999. PMID: 10529562

5

Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group.

Iversen P, Tveter K, Varenhorst E. Iversen P, et al. Scand J Urol Nephrol. 1996 Apr;30(2):93-8. doi: 10.3109/00365599609180896. Scand J Urol Nephrol. 1996. PMID: 8738052 Clinical Trial.

6

A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6.

Iversen P, Tammela TL, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, Viitanen J, Hoisaeter P, Lundmo P, Rasmussen F, Johansson JE, Persson BE, Carroll K; Scandinavian Prostatic Cancer Group (SPCG). Iversen P, et al. Eur Urol. 2002 Sep;42(3):204-11. doi: 10.1016/s0302-2838(02)00311-1. Eur Urol. 2002. PMID: 12234503 Clinical Trial.

7

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.

Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, Chamberlain M, Carroll K, Gotting-Smith K, Blackledge GR. Iversen P, et al. Urology. 1998 Mar;51(3):389-96. doi: 10.1016/s0090-4295(98)00004-1. Urology. 1998. PMID: 9510340 Clinical Trial.

8

Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: a population based registry study.

Brasso K, Friis S, Juel K, Jørgensen T, Iversen P. Brasso K, et al. Among authors: iversen p. J Urol. 1999 Feb;161(2):524-8. J Urol. 1999. PMID: 9915440

9

Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). International Casodex Investigators.

Iversen P. Iversen P. Eur Urol. 1994;26 Suppl 1:5-9. Eur Urol. 1994. PMID: 7737258 Clinical Trial.

10

Combined androgen blockade in the treatment of advanced prostate cancer--an overview. The Scandinavian Prostatic Cancer Group.

Iversen P. Iversen P. Scand J Urol Nephrol. 1997 Jun;31(3):249-54. doi: 10.3109/00365599709070342. Scand J Urol Nephrol. 1997. PMID: 9249887 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

942 results

Search Page

Filters